{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Longeveron",
            "NStudiesAvail": 430108,
            "NStudiesFound": 8,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 8,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Change from baseline in physical function will be measured to assess Patient-Reported Outcome Measurement compared to placebo at 180 days post infusion.",
                              "Change in serum TNF-alpha compared to placebo"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in patient reported outcome of overall physical function capacity using the PROMIS-Physical Function-Short Form 20a compared to placebo",
                              "Change in TNF-alpha compared to placebo"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "180 days post-infusion",
                              "180 days post-infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Plasma levels of interleukins measured in pg/mL.",
                              "Change in Clinical Frailty rating",
                              "Change in risk of falling",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Change in subject quality of life as assessed by participant-reported outcomes.",
                              "Number of participants that die from any cause while enrolled on the trial and after being treated with LMSCs.",
                              "Change by participant-reported outcomes. Minimum 16 (no concern about falling) to maximum 64 (severe concern about falling)",
                              "Plasma levels of B & T Cells.",
                              "Distance in meters walked in 6 minutes",
                              "Short Physical Performance Battery Assessment",
                              "TInetti POMA assessment",
                              "Weigh measurements at visits",
                              "Handgrip strength via dynamometer."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:",
                              "Differences in rate of decline from Aging Frailty",
                              "Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment",
                              "PROMIS Short Form 20a questionnaire",
                              "PROMIS Mobility questionnaire",
                              "PROMIS Upper Extremity questionnaire",
                              "Short Form 36 questionnaire",
                              "IIEF questionnaire",
                              "SQOL-F questionnaire",
                              "Death from any cause",
                              "Falls Efficacy Scale-International (FES-I)",
                              "Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:",
                              "Rate of decline in Aging Frailty status as assessed by the 6 minute walk test",
                              "Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)",
                              "Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test",
                              "Rate of decline in Aging Frailty status as assessed by the Weight Loss",
                              "Rate of decline in Aging Frailty status as assessed by the Handgrip Test"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Within 12 months after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion",
                              "Baseline, month 6 and month 12 after infusion"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Neurological/neurocognitive assessments. ADAS-Cog 11 (Alzheimer's Disease Assessment Scale-cognitive subscale 11) MMSE (Mini Mental State Examination) NPI (Neuropsychiatric Inventory) UPSIT (University of Pennsylvania Smell Identification Test) GDS (Geriatric Depression Scale)\nQuality of life assessments. ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) QOL-AD (Quality of Life-Alzheimer's Disease)\nBlood inflammatory and AD biomarkers. IL-1 IL-6 TGF-\u03b21 TNF-\u03b1 CRP D-Dimer Fibrinogen ApoE\nCerebrospinal fluid (CSF) inflammatory biomarkers. IL-1 IL-6 TGF-\u03b21 TNF-\u03b1\nCSF biomarkers of AD. Tau. Phosphorylated tau. Beta-amyloid.\nBrain volumetry calculated using MRI, including:\n\nHippocampal volume. Ventricular volume. Whole-brain volume."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Preliminary efficacy will be determined by examining for changes in AD status and rate decline as assessed by the following."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At Baseline, 2, 4, 13, 26, 39, and 52 weeks"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function.",
                              "Used to assess cardiac function. Measured by serial echocardiograms and MRI.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Used to assess change in somatic growth.",
                              "Treatment-Emergent Adverse Events will be assessed via incidence of co-morbidity, which include: cardiovascular morbidity; need for transplantation; re-hospitalizations; cardiovascular mortality; and all-cause mortality."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Efficacy: Change from baseline in right ventricular ejection fraction (%).",
                              "Efficacy: Change from baseline in right ventricular end-systolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic volume.",
                              "Efficacy: Change from baseline in right ventricular end-diastolic diameter.",
                              "Efficacy: Change from baseline tricuspid regurgitation.",
                              "Efficacy: Change in weight (in kilograms).",
                              "Efficacy: Change in height (in centimeters).",
                              "Efficacy: Change in head circumference (in centimeters).",
                              "Efficacy: Number of patients with Treatment-Emergent Adverse Events, and total number of occurrences of Treatment-Emergent Adverse Events, through-out participation in trial."
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment.",
                              "Evaluated through 1 year post-treatment."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Endothelial function (FMD, EPC function) Inflammatory markers (CBC with differential, TNF\u03b1, CRP, IL-1, IL-6, D-dimer, Fibrinogen) Heart function and structure (Dobutamine Stress Echocardiography) Blood pressure Lipid profile (HDL; LDL; triglycerides; cholesterol) Physical activity (6 minute walk test and CHAMPS questionnaire) Lung function (spirometry) Glycemia (hemoglobin A1c;fasting glucose; urine glucose) Weight Subject quality of life (QOL) (QOL assessments)."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Difference in rate of change in the metabolic syndrome as defined by the following:"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, 3 month, 6 month and 12 months."
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "as measured by serial echocardiograms and MRI scans.",
                              "Assessed through the number of participants with adverse events, hospitalizations, or transplantations.",
                              "Changes in weight, height, and head circumference will be measured",
                              "Assessment of cardiovascular mortality, all-cause morbidity, Cardiovascular morbidity, re-hospitalizations, need for transplantation."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation",
                              "Number of participants with incidence of mortality or need for transplantation after the BDCPA operation",
                              "Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation",
                              "Assessment of Co-morbidity"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "baseline, 24 weeks and 1 year",
                              "One year after injections",
                              "12 months post operative",
                              "up to 12 months follow-up"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 7,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Geometric mean titer",
                              "Change in overall assessment via Lung imaging via chest X-ray will be assessed and compared between baseline and 6 months",
                              "Change in overall assessment via Lung imaging via computerized tomography will be assessed and compared between baseline and 6 months"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Immunity",
                              "Change in Imaging via X-ray",
                              "Change in Imaging via Computerized Tomography"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline to 6 Months",
                              "Baseline to 6 Months",
                              "Baseline to 6 Months"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 8,
                        "ResultsFirstSubmitDate": [
                              "March 30, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "March 30, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire measures duration of exercise-related activities (hours/week). The Duration variable can range from 0 - 399.75 hours per week. Higher scores indicate more activity.",
                              "4-meter gait speed test measures the time (in seconds) taken to walk a distance of 4 meters. The total score has a range of 1 point - 4 points with the higher score indicating faster walk speed.",
                              "Standard Physical Performance Battery (SPPB) Assessment has total score ranging from 0-4 with the higher score indicating better balance.",
                              "Change in weight as measured in kilograms (kg).",
                              "Hand grip strength as assessed by a dynamometer. Grip strength is recorded (in mmHg) three times for each hand. The average reading is reported for each hand.",
                              "Multi-dimensional Fatigue Inventory (MFI) Questionnaire contains 20 questions with a 5-point scale. The MFI has total score ranging from 20-100 with the higher score indicating less fatigue.",
                              "Investigating Choice Experiences for the Preferences of Older People (ICEpop) Capability measure for Older people (ICECAP) questionnaire has total score ranging from 5-20 with the higher score indicating greater quality of life.",
                              "Short Form (SF)-36 Questionnaire has consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. Lower scores indicate the more disability, and higher scores indicate less disability.",
                              "EuroQoL (EQ)- 5 Dimension (5D)- 3 levels (3L) Questionnaire has total score ranging from 0-10 for the 5 dimensions. Higher scores indicate better Quality of Life.",
                              "EuroQoL - 5 Dimension - 3 levels (EQ-5D-3L) Overall health status question has a range of 0-100. Higher scores indicate better Quality of Life.",
                              "University of Pennsylvania Smell Identification Test (UPSIT) smell test booklet has a total score ranging from 0-40 with higher scores indicating better olfaction.",
                              "Any reported death from any cause.",
                              "Change in dobutamine stress echocardiogram induced ejection fraction",
                              "Change in inflammatory markers including C-Reactive Protein (CRP) and Fibrinogen serum samples as measured in mg/L.",
                              "Change in inflammatory markers including Interleukin (IL)-6 and Tumor Necrosis Factor (TNF) Alpha from serum samples as measured in pg/mL.",
                              "Change in inflammatory marker D-Dimer from serum samples as measured in mg/dL."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Change in Frailty as Assessed by CHAMPS Questionnaire",
                              "Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test",
                              "Change in Slowing of Mobility as Measured by SPPB",
                              "Change in Weight",
                              "Change in Diminished Hand Grip Strength",
                              "Change in Exhaustion as Measured by the MFI Questionnaire",
                              "Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire",
                              "Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire",
                              "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire",
                              "Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale.",
                              "Change in Sense of Smell as Measured by UPSIT",
                              "Death",
                              "Change in Ejection Fraction (EF)",
                              "Change in Inflammatory Markers Levels",
                              "Change in Inflammatory Markers",
                              "Change in Inflammatory Marker D-dimer Levels"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "Up to 12 months.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit.",
                              "At baseline and 6 month follow-up visit."
                        ],
                        "SeeAlsoLinkLabel": [
                              "Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://isci.med.miami.edu"
                        ],
                        "SeriousEventAssessmentType": [
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment",
                              "Systematic Assessment"
                        ],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  }
            ]
      }
}